An article on the front page of today’s Wisconsin State Journal covers a a new research study on psilocybin at the University of Wisconsin. In UW Madison tunes in to “magic mushroom” medicine, writer David Wahlberg describes the work of researcher Paul Hutson and his team at the UW School of Pharmacy. Hutson enlisted 12 volunteers for three sessions with psilocybin at doses of 20, 30, and 40 mg per 70 kg of body weight.
An article by Heffter researcher Matthew Johnson and his colleagues is bringing international media attention to the promise of psychedelic therapy. “Psychedelic Medicine: A Reemerging Therapeutic Paradigm,” published in the Canadian Medical Association Journal, reviews the use of psychedelics for treating serious disorders including anxiety, addiction, and PTSD. The authors conclude that psychedelic substances “may offer new ways to treat mental illness and addiction in patients who do not benefit from currently available treatments.” They also
Blogger Andrew Penn continues his series on psychedelics with an entry about the challenges that face mental health professionals who study and work with these substances. In “Psychedelics: What to Tell Patients Today,” Penn discusses the problem of explaining psychedelic therapy to patients who may be enthusiastic about the subject but unaware of potential negative consequences. Penn also presents a list of challenges for future research as well as questions for clinicians and researchers. “As studies
The PsychCongress Network, a website devoted to news for mental health professionals, is featuring a series of articles on the use of psychedelics in psychotherapy. The most recent entry, “How Psychedelics May Be Used to Accelerate Psychotherapy,” covers research using psilocybin and MDMA for treating PTSD, cancer anxiety, and substance abuse. The author cites Heffter-sponsored research at Johns Hopkins University and the University of New Mexico. “These findings are as fascinating as they are bewildering. Why
A new documentary titled Dying to Know chronicles the friendship of two twentieth century icons, Timothy Leary and Richard Alpert, aka Ram Dass. Their research at Harvard fifty years ago inspired the psychedelic movement of the 1960s. Producer/Director Gay Dillingham worked with Heffter on a project documenting the use of psilocybin to treat alcoholics. Dying to Know, narrated by Robert Redford, premieres in Bay Area theaters on July 10th.
The Heffter Research Institute is sponsoring another study on psilocybin and mystical experience. Researchers Stephen Ross and Anthony Bossis at the New York University School of Medicine are studying the effects of psilocybin on individuals who lead religious congregations or spiritual communities. The link below is for a flyer that describes the study and gives contact information for people who would be interested in volunteering. “Leaders from all traditions are invited to volunteer. Participants will receive psilocybin
The Heffter Research Institute is proud to sponsor this year’s International Forum on Consciousness (formerly the BioEthics Forum) held May 7th and 8th on the Madison, WI, campus of the BioPharmaceutical Technology Center. We’ll see you there! Coordinated by Promega Corporation and the BTC Institute, the International Consciousness Forum promises a lively two days of information-sharing and discussion regarding important – and often challenging – topics related to the exploration of consciousness. As always, the
A feature article in The Independent profiles a Norwegian married couple and their goal of providing access to quality psychedelics. Clinical psychologist Pål-Ørjan Johansen and his wife Teri Kreb, a research fellow in the Department of Neuroscience at the Norway University of Science and Technology, aim to reform drug policy in the interest of scientific research and human rights. They established a non-profit foundation, EmmaSofia, to manufacture pharmaceutical-grade MDMA and psilocybin. “Speaking on the website of the
The Purdue Exponent, the daily student newspaper of Purdue University, has a feature article on the work of David Nichols, the co-founder and President of the Heffter Research Institute. Staff writer Danielle Wilkinson covers Dr. Nichols’ research on the psychedelic chemicals MDMA (“Ecstasy”) and LSD. “’We made LSD analogues and derivatives in an attempt to understand why LSD was so potent, and also how it might interact with brain receptors,’ said Nichols. ‘Then as my
The OPEN Foundation, a Dutch organization that supports psychedelic research, published the second part of a special issue in the journal Current Drug Abuse Reviews. Three new articles focus on the use of psychedelics for treating addiction, including an article on the Heffter-supported study on tobacco addiction at Johns Hopkins University. Other article topics include the potential of psychedelics in healthcare and a review of LSD in the treatment of addictions. Second part of special